Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prothena CEO Dale Schenck Dies From Pancreatic Cancer

Executive Summary

Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.

Advertisement

Related Content

Lilly's Leap Tests Investors' Faith In Solanezumab
JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure
Prothena reveals positive amyloidosis data; CEO's cancer
Roche in $600m deal for Parkinson's antibody program
From Tysabri to bapi and back to the drawing board: Dale Schenk speaks
Prothena spins out of Elan
Pfizer and partners pull plug on bapineuzumab for Alzheimer's after second Phase III failure

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel